Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OncoFetal_Ploidy

Financiado

Cerrado

Understanding aneuploidy tolerance in cancer by studying early embryogenesis

Can we study complex cancer biology by using a more predictable and structured model of embryogenesis? Many of the hallmarks of cancer biology are shared with the biology of embryos: sustained proliferation, migratory behavior, an... ver más

30/11/2024

NKI AVL

Presupuesto desconocido

Líder del proyecto

STICHTING HET NEDERLANDS KANKER INSTITUUTANTO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-11-30

HORIZON-MSCA-2021-PF-01-01: MSCA Postdoctoral Fellowships 2021 ExpectedOutcome:

I+D

Cerrada hace 3 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

NKI AVL

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ANEUPLOIDY Molecular origins of aneuploidies in healthy and diseased hu... 10M€ Cerrado

BFU2011-27568 ESTUDIO DEL MARCO MOLECULAR RESPONSABLE DEL INICIO DE LA SAL... 99K€ Cerrado

SAF2013-43801-P CELULAS INICIADORAS DEL CANCER DE MAMA: IMPACTO DE LA TETRAP... 97K€ Cerrado

NOANEUPLOIDY Mechanisms that prevent aneuploidy 2M€ Cerrado

MADCIN Defining the Impact of Chromosome Instability in Tumor Initi... 2M€ Cerrado

BFU2016-77975-R MECANISMOS MOLECULARES NECESARIOS PARA EL MANTENIMIENTO DE L... 169K€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2022-07-01
Fecha Fin: 2024-11-30

Líder del proyecto

STICHTING HET NEDERLANDS KANKER INSTITUUTANTO... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Can we study complex cancer biology by using a more predictable and structured model of embryogenesis? Many of the hallmarks of cancer biology are shared with the biology of embryos: sustained proliferation, migratory behavior, angiogenesis, immune system suppression, and in my opinion the most fascinating: the tolerance of genome instability.Chromosome segregation errors and resulting aneuploidy are an important source of intratumor heterogeneity, therapy resistance, and metastasis in cancer. On the other hand, aneuploidy is detrimental during development. However, despite the detrimental effects of aneuploidy, most human pre-implantation embryos are mosaics of euploid and aneuploid cells, and the proportion of aneuploid cells is progressively depleted from embryos as the cell differentiation progresses from the blastocyst stage onwards. Therefore, could it be the undifferentiated state or de-differentiation of cells that might play a role in aneuploidy tolerance? Here I plan to study and compare aneuploidy tolerance during embryogenesis and in cancer, and investigate if differentiation and de-differentiation of cells play a role in this phenomenon. In the suggested experiments I will examine cells' response to chromosome segregation errors in human embryonic stem cell gastruloids (hESC), colorectal cancer organoids (CC), and normal colon organoids (NC) after aneuploidy induction with Msp1 inhibitor (+/- CENP-E inhibitors). Specifically, I will assess the cell proliferation rate, cell cycle progression and apoptosis with live-cell imaging, as well as transcriptional profiles using single-cell RNA-seq. Next, I will assess the same phenotypes after the addition of different growth factors that change the differentiation state of the cells. Ultimately, I would like to find the patterns shared between cancer cells and embryonic stem cells, which could be exploited for novel cancer therapies that would not be detrimental to somatic cells.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores